ZyVersa Therapeutics, Inc.
ZVSA
$0.7151
$0.00711.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 89.34% | 17.27% | 96.48% | 20.24% | -185.18% |
| Total Depreciation and Amortization | 93.13% | -98.57% | 300.00% | 0.00% | -4,465.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -97.65% | 7.64% | -99.78% | 190.74% | 48,552.21% |
| Change in Net Operating Assets | 94.41% | -6.10% | -77.50% | -78.96% | -257.41% |
| Cash from Operations | 56.07% | 31.18% | -369.60% | 17.71% | 26.84% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -39.19% | -73.00% | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 37.58% | 67.25% | -- | -- | -1,720.33% |
| Cash from Financing | -39.43% | -71.67% | 100.00% | 7,801.73% | 747.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.69% | -99.75% | -82.40% | 76.12% | 147.28% |